PURE Bioscience  

(Public, OTCMKTS:PURE)   Watch this stock  
Find more results for NASDAQ:PURE
-0.010 (-1.67%)
May 29 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.57 - 0.60
52 week 0.34 - 1.22
Open 0.57
Vol / Avg. 8,980.00/21,012.00
Mkt cap 24.08M
P/E     -
Div/yield     -
EPS -0.26
Shares 40.82M
Beta 0.58
Inst. own 3%
Mar 4, 2015
Q2 2015 PURE Biosciences Inc Earnings Call - Webcast
Mar 4, 2015
Q2 2015 PURE Biosciences Inc Earnings Release

Key stats and ratios

Q1 (Jan '15) 2014
Net profit margin -635.90% -2009.09%
Operating margin -635.90% -2031.82%
EBITD margin - -1618.18%
Return on average assets -110.03% -563.63%
Return on average equity -127.27% -
Employees 12 -
CDP Score - -


EL CAJON, CA 92020
United States - Map
+1-619-5968600 (Phone)
+1-619-5968690 (Fax)

Website links


Pure Bioscience, Inc. is focused on developing and commercializing antimicrobial products primarily in the food safety arena that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on patented stabilized ionic silver, and initial products contain silver dihydrogen citrate (SDC). SDC is manufactured as a liquid delivered in various concentrations. The Company currently manufactures and distributes SDC-based disinfecting and sanitizing products, which are registered by the Environmental Protection Agency (EPA).

Officers and directors

David Pfanzelter Independent Chairman of the Board
Age: 59
Henry R. Lambert Chief Executive Officer, Director
Age: 62
Peter C. Wulff Chief Financial Officer, Chief Operating Officer, Corporate Secretary
Age: 54
Gary D Cohee Director
Age: 68
Tom Y Lee CPA Director
William Otis Independent Director
Age: 57
David M. Theno Jr. Ph.D. Independent Director
Age: 62